CCTV exposed Zhengda Tianqing company involved in commercial bribery

Source: in the evening of September 11, 2013, the focus interview of caijing.com took "the trade behind tourism" as the title, and exposed that Zhengda Tianqing organized more than ten doctors to attend the academic conferences in Thailand and Taiwan, respectively, and organized doctors to travel and consume, involving drugs of Ganping and Runzhong According to the focus interview, according to the Interim Provisions on the prohibition of commercial bribery, medical personnel taking advantage of their position to accept the property of pharmaceutical enterprises constitutes the "crime of bribery of non state staff", which also includes the receipt of token cards and travel expenses Zhengda Tianqing is the main holding subsidiary of China biopharmaceutical Since July this year, Chinese government agencies have strictly investigated the bribery of GSK and other multinational pharmaceutical companies At present, many GSK executives have been detained and may face huge fines The market has been worried that the anti-corruption storm will affect the mainland pharmaceutical enterprises, so the Zhengda Tianqing was exposed by CCTV and attracted the attention of the market On September 12, China's biopharmaceutical industry fell nearly 25% at the beginning of trading, and trading volume was 14 times larger than the previous trading day In response, sun Fengqiang, an analyst of Guotai Junan pharmaceutical industry (Hong Kong), told reporters that the exposure only mentioned tourism in the academic conference, but did not mention serious problems such as cash transaction and drug quality The intensity of the attack was far less than the exposure of GSK Regarding the impact of the exposure on the company's business performance, sun Fengqiang believes that in the short term, the exposure will affect the company's clinical sales, and the growth in the second half of the year may be temporarily affected, but the impact is estimated to be limited In the long run, the company is still the most competitive local pharmaceutical enterprise in China "Specifically, the drug Runzhong entecavir dispersible tablets involved in this exposure accounted for 16% of China's biomedical sales in the first half of this year, and the profit contribution should be more than 20% Runzhong is used as hepatitis medicine Patients need to take it daily for a long time It is sticky and will not change the brand after use It is estimated that the direct impact of the event on the sale of the drug can be ignored As for Ganping, it only accounted for 4% of China's biomedical sales in the first half of the year, not much, "said sun Sun Fengqiang also pointed out that "among the domestic pharmaceutical enterprises, Zhengda Tianqing is one of the most standardized enterprises in clinical promotion The degree of standardization of its academic promotion is far higher than the overall situation of the industry dominated by cash transactions, even higher than some transnational pharmaceutical enterprises This time, it was exposed or framed by competitors." It is reported that Zhengda Tianqing is a leading chemical manufacturer in China, and the market value of China's biomedical industry is close to 30 billion Hong Kong dollars.